Antineoplastic Agents: Miscellaneous
OTYKE1 “Tykerb tablet” 250 mg/tab
適應症：在和capecitabine併用的情況下，Tykerb適用於治療腫瘤有HER2 (ErbB2)過度表現之現象且曾接受anthracycline、taxane以及trastuzumab治療後病況惡化之後期或轉移性乳癌患者。在和芳香酶抑制劑(aromatase inhibitor)併用的情況下，Tykerb適用於治療Her2/neu (ErbB2)過度表現，荷爾蒙接受體呈陽性之轉移性乳癌患者，但未曾接受過trastuzumab或芳香酶抑制劑治療，且目前不打算進行化療之停經後婦女。
Usual dose:
Breast cancer, Postmenopausal women, HER2 overexpression, in combination with letrozole: 1500 mg PO qd continuously in combination with letrozole 2.5 mg PO qd.
Adverse effect:
Common: hand-foot syndrome due to cytotoxic therapy, rash, diarrhea, indigestion, nausea, vomiting, anemia thrombocytopenia, ALT/SGPT level raised, AST/SGOT level raised, hyperbilirubinemia, backache, pain in limb, headache, insomnia, dyspnea, fatigue.
Serious: depression of left ventricular systolic function, prolonged QT interval, hepatotoxicity, hypersensitivity reaction, interstitial lung disease, pneumonitis.
健保使用規範：（103/9/1）
1.與capecitabine併用，使用於曾接受anthracycline,taxane以及trastuzumab治療後病況惡化之轉移性乳癌併有腦部轉移，且為HER2過度表現患者。
2.需經事前審查核准後使用，每次申請療程以三個月為限。再申請應檢附前次治療結果評估資料。